Clinical trial NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Official title: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Early Alzheimers Disease
Keywords: Early Alzheimers disease
Early AD
AD
mild cognitive impairment
MCI
buntanetap
posiphen
Lead sponsor: Annovis Bio Inc.
Sponsor class: INDUSTRY
Collaborators: name: Prevail Infoworks
First posted: 2024-11-29
Enrollment: 760
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

* Take buntanetap/Posiphen or a placebo every day for 18 months
* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
* Complete pre- and post-clinic visit phone calls


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.
2. Male or female, aged 55 - 85 years.
3. MMSE 21-28 at screening and baseline.
4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.
5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.
6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.
8. Female participants of childbearing potential\* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

   * Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
   * Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
   * Intrauterine device (IUD),
   * Intrauterine hormone-releasing system (IUS),
   * Bilateral tubal occlusion,
   * Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),
   * Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

     * Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

   * Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
   * Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
   * IUD,
   * IUS,
   * Bilateral tubal occlusion.
10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent.
11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    * Cholinesterase inhibitors and/or memantine medication,
    * Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    * Mood-stabilizing psychotropic agents including, but not limited to, lithium.
13. Adequate visual and hearing ability (physical ability to perform all the study assessments).
14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.
3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct \> 1 cm3, \> 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).
5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.
6. Has bradycardia (\<50 bpm) or tachycardia (\>100 bpm) on the ECG at screening and deemed medically significant by the PI.
7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.
8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \<60 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) \> 2.0 ULN and/or total bilirubin \> 2.0 ULN).
9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.
10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
14. Participants with learning disability or developmental delay.
15. Participants whom the PI deems to be otherwise ineligible.
16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:
    * Silicified Microcrystalline Cellulose
    * Dibasic Calcium Phosphate Dihydrate
    * Mannitol
    * Stearic Acid
    * Hypromellosee (capsule shells structure)
    * Titanium dioxide (opacifier of the capsule shells)
17. Participant is currently pregnant, breast-feeding, and/or lactating.
18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.
19. Participants with uncontrolled hypertension (systolic \>160mm Hg and/or diastolic \>95mm Hg) or hypotension (systolic \<90mm Hg and/or diastolic \<60 mm Hg) and deemed medically significant by the PI.

Primary outcomes:
measure: Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
timeFrame: From screening to 6-month readout, to end of treatment at 18 months.
measure: Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
timeFrame: From screening to 6-month readout, to end of treatment at 18 months.
Secondary outcomes:
measure: Mini Mental State Examination Score (MMSE)
timeFrame: From screening to 6-month readout, to end of treatment at 18 months.
measure: Volumetric MRI (hippocampus and whole brain)
timeFrame: At enrollment and the 6-month and 18-month visits.
measure: Clinical Global Impression - Severity (CGI-S) Scale
timeFrame: From screening to 6-month readout, to end of treatment at 18 months.
measure: Clinical Dementia Rating (CDR)
timeFrame: From screening to 6-month readout, to end of treatment at 18 months.
Other outcomes:
Locations:
city: Canoga Park
country: United States
facility: Hope Clinical Research
state: California
city: Englewood
country: United States
facility: CenExel Rocky Mountain
state: Colorado
city: Norwalk
country: United States
facility: Research Center for Clinical Trials
state: Connecticut
city: Boca Raton
country: United States
facility: SFM Clinical Research
state: Florida
city: Clermont
country: United States
facility: K2 Medical Research
state: Florida
city: Daytona Beach
country: United States
facility: K2 Medical Research Daytona
state: Florida
city: Fort Myers
country: United States
facility: Neuropsychiatric Research Center
state: Florida
city: Hallandale Beach
country: United States
facility: Velocity Clinical
state: Florida
city: Jacksonville
country: United States
facility: Jacksonville Center for Clinical Research
state: Florida
city: Lady Lake
country: United States
facility: K2 Medical Research
state: Florida
city: Lake Worth
country: United States
facility: Headlands Research JEM
state: Florida
city: Lakeland
country: United States
facility: Accel Research Sites Lakeland (Alcanza)
state: Florida
city: Maitland
country: United States
facility: K2 Medical Research
state: Florida
city: Merritt Island
country: United States
facility: Flourish Research/Merritt Island Medical Research
state: Florida
city: New Port Richey
country: United States
facility: Suncoast Clinical Research
state: Florida
city: Orlando
country: United States
facility: Conquest Research
state: Florida
city: Winter Park
country: United States
facility: Conquest Research
state: Florida
city: Decatur
country: United States
facility: Accel Neurosciences
state: Georgia
city: Gainesville
country: United States
facility: CARE (Center for Advanced Research & Education)
state: Georgia
city: Honolulu
country: United States
facility: Hawaii Pacific Neuroscience
state: Hawaii
city: Chicago
country: United States
facility: Great Lakes Clinical Trials/Flourish Research
state: Illinois
city: Indianaopolis
country: United States
facility: JWM Research
state: Indiana
city: Pikesville
country: United States
facility: Headlands Research Pharmasite
state: Maryland
city: Plymouth
country: United States
facility: Headlands Research Easter Massachusetts
state: Massachusetts
city: Springfield
country: United States
facility: Elixia MA
state: Massachusetts
city: Farmington Hills
country: United States
facility: Quest Research Institute
state: Michigan
city: Flowood
country: United States
facility: Precise Research Center
state: Mississippi
city: Chesterfield
country: United States
facility: Headlands Research CRP
state: Missouri
city: Toms River
country: United States
facility: Cenexel Advanced Medical Research of New Jersey (AMRI)
state: New Jersey
city: West Long Branch
country: United States
facility: Advanced Clinical Institute
state: New Jersey
city: Brooklyn
country: United States
facility: SPRI
state: New York
city: Hyde Park
country: United States
facility: Parker Jewish Institute for Health Care and Rehab
state: New York
city: Lake Success
country: United States
facility: Neurological Associates of Long Island
state: New York
city: Staten Island
country: United States
facility: Richmond Behavioral Associates
state: New York
city: Syracuse
country: United States
facility: Ichor Research
state: New York
city: Durham
country: United States
facility: Duke University
state: North Carolina
city: Matthews
country: United States
facility: AMC Research/Flourish Research
state: North Carolina
city: Beavercreek
country: United States
facility: American Clinical Research Center
state: Ohio
city: Centerville
country: United States
facility: Valley Medical Research
state: Ohio
city: Oklahoma City
country: United States
facility: Lynn Health Science Institute
state: Oklahoma
city: Portland
country: United States
facility: Summit Headlands
state: Oregon
city: Media
country: United States
facility: Suburban Research Associates
state: Pennsylvania
city: East Providence
country: United States
facility: Rhode Island Mood and Memory Research Institute
state: Rhode Island
city: Summerville
country: United States
facility: Palmetto Primary Care & Specialty Physicians
state: South Carolina
city: Austin
country: United States
facility: Senior Adults Specialty Healthcare
state: Texas
city: Round Rock
country: United States
facility: Central Texas Neurology Associates
state: Texas
city: Arlington
country: United States
facility: Sana Research
state: Virginia
Study officials:
References: